Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Biotech
Boehringer signs $1.3B MASH collab with RNA biotech Ochre
Boehringer Ingelheim is making yet another bet that RNA therapies hold the key to treating metabolic-associated steatohepatitis.
James Waldron
Apr 22, 2024 8:45am
Ionis raises hand in MASH race, shows liver gains in ph. 2 test
Mar 13, 2024 9:54am
Boehringer links GLP-1 agonist to scarring improvements in MASH
Feb 26, 2024 6:17am
Inventiva pauses MASH study over patient's raised liver enzymes
Feb 16, 2024 8:15am
Hepatitis B drug developers chart slow progress, just like hep C
Nov 14, 2023 9:05am
Inventiva stock climbs on delayed data from liver disease trial
Jun 14, 2023 6:00am